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The BCG vaccine does not protect against COVID-19.
Evidence from a natural experiment in Sweden.
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The Bacille Calmette-Gue´rin (BCG) tuberculosis vaccine has immunity bene-
fits against respiratory infections. Accordingly, it has been hypothesized that
it may have a protective effect against COVID-19. 12 randomized controlled
trials are currently underway to test this hypothesis, but their results shall not
be available before at least five months. Instead, this paper uses a nationwide
natural experiment. In April 1975, Sweden discontinued newborns BCG vac-
cination. The vaccination rate fell from 92% to 2%. I compare the numbers
of COVID-19 cases and hospitalizations for cohorts born just before and just
after that change. I find no statistically significant differences, and I can reject
small BCG effects. Thus, receiving the BCG vaccine at birth does not seem to
have a protective effect against COVID-19.
One Sentence Summary: Having received the BCG vaccine at birth does not protect hu-
mans against COVID-19.
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Introduction
The Bacille Calmette-Gue´rin (BCG) tuberculosis vaccine has immunity benefits against non-
targeted pathogens (1), and in particular against respiratory infections (2). Accordingly, it has
been hypothesized that BCG vaccination may have a protective effect against COVID-19. In
fact, (3,4) have found that countries with universal Bacillus Calmette-Gue´rin (BCG) childhood
vaccination policies tend to be less affected by the COVID-19 pandemic, in terms of their
number of cases and deaths. As of June 5th 2020, 12 randomized controlled trials (RCTs)
studying the protective effect of the BCG against COVID-19 are already registered on https:
//clinicaltrials.gov/. None has a primary completion date earlier than October 1st
2020, so these RCTs’ first results will not be known until at least five or six months.
Instead, I test this hypothesis by leveraging a natural experiment, where a group of individu-
als received the BCG vaccine while another group of comparable individuals did not receive it,
without the intervention of investigators. Sweden currently has the 5th highest ratio of COVID-
19 deaths per capita in the world. In April 1975, it stopped its newborns BCG vaccination
programme, leading to a drop of the BCG vaccination rate from 92% to 2% for cohorts born
just before and just after the change (5). I compare the number of COVID-19 cases, hospital-
izations, and deaths per capita, for cohorts born just before and just after April 1975, a method
designed by social scientists, called a regression discontinuity (RD), and deemed as reliable
as RCTs (6). Those cohorts do not have different numbers of COVID-19 cases per capita, as
shown in Figure 1 below, where the red vertical line represents the discontinuation of the BCG
vaccination policy in April 1975. Figures 2 and 3 at the end of the manuscript show similar
results for the numbers of hospitalizations and deaths per capita.
My study exemplifies the potential of combining historical analysis of past medical policies
with statistical techniques designed in the social sciences to answer current medical questions.
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Figure 1: Cases per 1000 inhabitants, per quarter of birth
This figure shows the number of COVID-19 cases per 1000 inhabitants per quarter of birth, from Q1-1930 to
Q4-2001. Q2-1975, when vaccination at birth was discontinued, is represented by the red vertical line.
Doing so can yield much faster answers than conducting an RCT. It can also yield results with
a much smaller statistical margin of error. In my statistical analysis, I can reject fairly small
effects of the BCG vaccine, because my study leverages a nationwide experiment. Achieving a
comparable statistical precision in an RCT would require including around 15,000 participants.
Sweden’s 1975 discontinuation of BCG vaccination at birth
In April 1975, Sweden stopped its mass newborns BCG vaccination programme. This change
had a dramatic effect on the BCG coverage rate. Based on nationwide reports on the vaccination
status of children below 7 sent to the National Bacteriological Laboratory in 1981, 92% of
children born in 1974 got vaccinated, against 26% of those born in 1975, and less than 2% of
those born between 1976 and 1980 (5). Among children born in 1975, most of the vaccinated
children were born in the first quarter of the year, when the universal vaccination policy was
still in place (5). Prior to that, Sweden had already eliminated its revaccination programme at
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7 years of age in 1965. Sweden also stopped its revaccination programme at 15 years of age
in 1986, four years before the 1975 cohort turned 15 years old. Finally, Sweden stopped its
vaccination program for conscripts in 1979, long before the 1975 cohort would do its military
service (7). Overall, children born before April 1st 1975 benefited from a BCG vaccination
policy at birth, while children born after that did not benefit from any BCG vaccination policy.
Results
This study uses the number of COVID-19 cases per 1000 inhabitants for quarterly birth co-
horts born between Q1-1930 and Q4-2001, the number of COVID-19 hospitalizations per 1000
inhabitants for cohorts born between Q1-1930 and Q4-1991, and the number of COVID-19
deaths per 1000 inhabitants for groups of three yearly birth cohorts, from 1930-1931-1932 to
1978-1979-1980. These variables were constructed using data compiled by the Public Health
Agency of Sweden, see the supplementary materials (SM) for details.
Figure 1 above shows that the number of COVID-19 cases per 1000 inhabitants is very
similar for cohorts born just before and just after April 1975. This suggests that universal BCG
vaccination does not change the number of COVID-19 cases per 1000 inhabitants for individuals
born in 1975. Figures 2 and 3 below show that similar conclusions apply when one looks at
the number of COVID-19 hospitalizations per 1000 inhabitants and at the number of COVID-
19 deaths per 1000 inhabitants. Those numbers are also very similar just before and just after
April 1975. The number of deaths per 1000 inhabitants is several orders of magnitudes higher
for older than for younger cohorts, so Figure 3 only presents those numbers for cohorts born
after 1960, to keep the graph legible.
Table 1 confirms this visual analysis. It reports RD estimates of the effect of the BCG
vaccination policy on COVID-19 outcomes, using the RD estimator proposed by (8) (see SM
for more details on the RD method and on that estimator). Effects of the BCG vaccination
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policy on cases per 1000 inhabitants and hospitalizations per 1000 inhabitants are small and not
statistically different from 0. Based on the confidence intervals in Column (3), we can reject
with 95% confidence that universal BCG vaccination reduces the number of cases per 1000
inhabitants by more than 0.409, an effect equivalent to 0.409/3.230 = 13% of the number of
cases per 1000 inhabitants in the 1975 cohort. For the number of hospitalizations per 1000
inhabitants, the effect we can reject is equal to 15% of the number of hospitalizations per 1000
inhabitants in the 1975 cohort. For deaths per 1000 inhabitants, I have only two data points
to the right of the Q2-1975 threshold. Therefore, I cannot compute the RD estimator for that
outcome, and have to rely instead on the visual analysis presented in Figure 3.
Discussion
It is possible to infer from Table 1 the effect of receiving the BCG vaccine at birth. Foreign-born
residents account for 27.2% of the Swedish population born in 1975 as per Statistics Sweden’s
data. They were not affected by the 1975 policy. Among natives, the policy led to a drop of the
vaccination rate from 92 to 2% (5). Assuming that the BCG vaccination rate of foreign-born
residents is the same just before and just after April 1975, a reasonable assumption as no other
European country changed its BCG vaccination policy in 1975, the policy led to a drop in the
BCG vaccination rate of 0.272 × 0 + (1 − 0.272) × (0.92 − 0.02) = 0.655. To convert the
effect of the policy change into the effect of being vaccinated at birth, one needs to divide the
effects in Table 1 by 0.655, the change in the BCG vaccination rate at birth induced by the
reform (9). One also needs to divide the confidence intervals by 0.655, which increases their
length by about 50%. Therefore, the relative effects of receiving the BCG vaccine at birth one
can reject based on Table 1 are 19% for COVID-19 cases per 1000 inhabitants and 23% for
COVID-19 hospitalizations per 1000 inhabitants.
Achieving a comparable statistical precision in an RCT would require an unrealistically
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large sample. Even with a COVID-19 hospitalization rate of 0.5%, as among the elderly
Swedish population, a randomized controlled trial with 15,000 participants would have a 95%-
level statistical margin of error of 1.96
√
0.005× 0.995/15, 000 = 0.001129. Then, that trial
could reject BCG effects larger than 0.001129/0.005 = 23% of the baseline hospitalization
rate, as in my study. My study’s precision comes from the fact it uses a nationwide experiment.
(10) have also used an RD to estimate the effect of changes in various BCG vaccination
policies on COVID-19 cases in Colombia, the Czech Republic, Thailand, Vietnam, and Singa-
pore. However, unlike what happened in Sweden in 1975, the policies they study did not lead
to large, documented changes in the BCG vaccination rate of consecutive birth cohorts, except
for Vietnam, a country with very few COVID-19 cases. Therefore, it is unclear whether those
policies can really be used to estimate the BCG’s effect, contrary to the policy I am studying.
Similarly, (11) have used a geographic RD comparing the number COVID-19 cases to the left
and to the right of the border between West and East Germany prior to reunification, as the
two countries had different BCG vaccination policies. However, a lot of migration between
the two territories happened after reunification, and the authors do not show that populations
currently residing in former West and East Germany still have very different BCG vaccination
rates. Moreover, many other things than just BCG vaccination policies differed between the two
countries prior to reunification.
This study’s results apply to cohorts born around 1975, namely middle-aged individuals
at the time of the pandemic. Even though some of the BCG protective effects tend to fade
rather than increase over time (12), it could still be the case that BCG vaccination at birth has
larger effects against COVID-19 on older than middle-aged individuals. When it generalized
BCG vaccination in the 1940s, Sweden simultaneously started vaccinating various age groups:
newborns in 1943, children entering and leaving school in 1944, and military conscripts in
1945 (13). BCG vaccination rates are not available for cohorts born in the 1930s and 1940s,
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but it seems likely that the vaccination rate increased gradually, so BCG introduction in Sweden
does not lend itself to an RD analysis. There may be other countries where BCG adoption
policies in the 1940s and 1950s have created discontinuous changes in the vaccination rate of
consecutive cohorts. Studying such policies would be extremely valuable.
Moreover, this study does not measure the COVID-19 immunity benefit conferred by a
recent BCG vaccination, as individuals born just before Q2-1975 were vaccinated 45 years ago.
The RCTs currently underway will tell if the protective effect of a recent BCG vaccination
differs from the effect measured in this study.
Overall, this study shows BCG vaccination at birth does not have a strong protective effect
against COVID-19. Thus, it seems that BCG childhood vaccination policies cannot account
for the differences in the severity of the pandemic across countries, as had been hypothesized
by prior studies (3). Moreover, my results come much before results of the RCTs studying
the protective effect of the BCG will be made available. While RCTs will complement this
study, by measuring the effect of a recent vaccination, this study still exemplifies the potential
of leveraging past medical policies and statistical techniques designed in the social sciences to
answer current medical questions.
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Table 1: Effect of BCG-at-birth policy on COVID-19 outcomes, in 1975 Swedish cohort.
Outcome Average in Effect of BCG 95% confidence
1975 cohort vaccination policy interval
(1) (2) (3)
Cases/1000 inhabitants 3.230 -0.002 [-0.409,0.405]
Hospitalizations/1000 inhabitants 0.758 0.089 [-0.112,0.291]
Notes. This table reports the estimated effect of the BCG-vaccination-at-birth policy on the COVID-19 outcomes
of the 1975 cohort in Sweden. The outcomes are the number of cases per 1000 inhabitants and the number of
hospitalizations per 1000 inhabitants. For each outcome, its average among the 1975 cohort is shown in Column
(1). The estimated effect of the BCG-vaccination-at-birth policy is shown in Column (2), and the 95% confidence
interval of this effect is shown in Column (3). Numbers in Columns (2) and (3) are computed using the rdrobust
Stata command, see (14).
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Figure 2: Hospitalizations per 1000 inhabitants, per quarter of birth
This figure shows the number of COVID-19 hospitalizations per 1000 inhabitants per quarter of birth, from Q1-
1930 to Q4-1991. The Q2-1975 threshold after which vaccination at birth was discontinued is represented by the
red vertical line.
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Figure 3: Deaths per 1000 inhabitants, per groups of 3 years of birth
This figure shows the number of COVID-19 deaths per 1000 inhabitants per groups of 3 yearly birth cohorts, from
birth cohorts 1960-1961-1962 to birth cohorts 1978-1979-1980. The 1975 threshold after which vaccination at
birth was discontinued is represented by the red vertical line.
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